ADC University
All you need to know about Antibody-Drug-Conjugates just a click away...
- The Next Generation Pharmaceuticals
- What Are Antibody-Drug Conjugates?
- How do ADCs work
- Monoclonal Antibodies
- Stable Linker (Technologies)
- Cytotoxic Agents
- Alpha-Amanitin
- Cryptophycin analog
- Cytotoxic agents and Antibody-drug Conjugates
- Deruxtecan
- Duocarmazine
- Calicheamicin
- Centanamycin (ML-970; indolecarboxamide)
- Dolastatins (Dolastatin 10 and Dolastatin 15)
- Duocarmycin analogues
- Maytansine
- Monomethyl Auristatin E (MMAE)
- Monomethyl Auristatin F (MMAF)
- Pyrrolobenzodiazepine (PBD)
- Targeting Cancer with Antibody-drug Conjugates
- Immunoglobulin G (IgG) antibody isotypes
- Antibody Dependent Cell-Mediated Cytotoxicity
- Glossary
- Changing Strategies in the War on Cancer – 1
- Characterization of Antibody-drug Conjugates
- Clinical Trials
- NCT01475006 (Clinical Trial/ AMG 595)
- NCT01522664 (Clinical Trial/ DEDN6526A/ RG7636/ RG-7636)
- NCT01631552 (Clinical Trial/ SACITUZUMAB GOVITECAN/ IMMU-132 / HRS7-SN38)
- NCT01902329 (Clinical Trial/ Vadastuximab Talirine)
- NCT01963052 (Clinical Trial/ AGS15E/ AGS-15ME)
- NCT01999738 (Clinical Trial / EC1456)
- NCT02099058 (Clinical Trial/ ABBV-399)
- NCT02134197 (Clinical Trial/ BAY1129980)
- NCT02213744 (HERMIONE) (Clinical Trial/ MM-302)
- NCT02326584 (Clinical Trial/ Vadastuximab Talirine)
- NCT02432235 (Clinical Trial/ ADCT-301)
- NCT02500914 (Clinical Trial/ SC-002)
- NCT02539719 (Clinical Trial/ SC-003)
- NCT02564900 (Clinical Trials/ DS-8201a)
- NCT02592876 (Clinical Trial Denintuzumab Mafodotin, SGN-CD19A)
- NCT02614560 (Clinical Trial/ Vadastuximab Talirine)
- NCT02848248 (Clincal Trial/ SGN-CD123A)
- SYD985 | trastuzumab vc-seco-DUBA | NCT02277717 (Clinical Trial)
- NCT01120184 (Marianne Trial)
- NCT02343406 (Clinical Trial/ ABT-414)
- NCT01741727 (Clinical Trial / ABT-414)
- NCT01800695 (Clinical Trial / ABT-414)
- NCT01114230 (Clinical Trial / AGS-16M8F)
- NCT01672775 (Clinical Trial/ AGS-16C3F/ AGS-16M8F/ AGS 16C3F)
- NCT01409135 (Clinical Trial/ ASG-22ME/ AGS-22M6E)
- NCT02091999 (Clinical Trial/ ASG-22CE)
- NCT01497821 (Clinical Trial/ AMG 172)
- NCT01228760 (Clinical Trial/ ASG-5ME)
- NCT01166490 (Clinical Trial/ ASG-5ME)
- NCT01439152 (Clinical Trial/ BAY94-9343)
- NCT02485119 (Clinical Trial/ BAY94-9343)
- NCT01028755 (Clinical Trial/ BAY79-4620)
- NCT01065623 (Clinical Trial/ BAY79-4620)
- NCT01100502 (Aethera Trial) (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00674947 (Clinical Trial/ BIIB015)
- NCT01771107 (Clinical Trial / Brentuximab Vedotin / SGN-035)
- NCT01461538
- NCT01393717
- NCT02388490
- NCT01780662 (Clinical Trial/ Brentuximab vedotin/ SGN-30)
- NCT01896999 (Clinical Trial/ Brentuximab vedotin/ SGN-035)
- NCT01421667
- NCT01805037
- NCT01940796
- NCT02096042 (Clinical Trials/ Brentuximab vedotin)
- NCT01657331(CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01851200 (Clinical Trial/ Brentuximab vedotin)
- NCT01616680
- NCT02423291
- NCT01492088 (Clinical Trial/ Brentuximab vedotin)
- NCT01900496 (Clinical Trial/ Brentuximab vedotin)
- NCT02227199 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01979536 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01700751 (Clinical Trial / Brentuximab Vedotin / SGN-035)
- NCT01902160 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01990534 (Clinical Trial/ Brentuximab Vedotin/ SGN-035)
- NCT02254239 (Clinical Trial/ Brentuximab vedotin)
- NCT02298257 (Clinical Trial/ Brentuximab Vedotin/ SGN-35)
- NCT01508312 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02244021 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01620229 (Clinical Trial/ Brentuximab vedotin)
- NCT01671813 (Clinical Trial/ Brentuximab vedotin/ SGN-035)
- NCT02169505 (Clinical Trial/ Brentuximab vedotin)
- NCT02164006 (Clinical Trial/ Brentuximab vedotin/ SGN-035)
- NCT01578499 (ALCANZA) (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02166463 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01925612 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01716806 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01807598 (Clinical Trial / Brentuximab vedotin / SGN-035 / Adcetris®)
- NCT01874054 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01522664 (Clinical Trial / DEDN6526A / RG7636)
- NCT01786135 (Clinical Trial / Denintuzumab mafodotin / SGN-CD19A / SGN-19A / hBU12-491)
- NCT01786096 (Clinical Trial / Denintuzumab mafodotin / SGN-CD19A / SGN-19A / hBU12-491)
- NCT01469793 (Clinical Trial / DMOT4039A / RG7600)
- NCT01832116 (Clinical Trial / DMOT4039A / RG7600)
- NCT02487979 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)
- NCT02363283 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)
- NCT02302339 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)
- NCT01997333 (CLINICAL TRIAL / GLEMBATUMUMAB VEDOTIN / CDX-011 / CR011-VCMMAE)
- NCT01156753 / Emerge Trial (CLINICAL TRIAL / GLEMBATUMUMAB VEDOTIN / CDX-011 / CR011-VCMMAE)
- NCT00704158 (Clinical Trial / Glembatumumab vedotin / CDX-011 / CR011-vcMMAE)
- NCT02422979
- NCT00412828 (CLINICAL TRIAL / GLEMBATUMUMAB VEDOTIN / CDX-011 / CR011-VCMMAE)
- NCT02064387 (Clinical Trial / GSK2857916 / J6M0-mcMMAF)
- NCT02001623 (Clinical trial / Tisotumab vedotin / HuMax®-TF-ADC / TF-011-MMAE)
- NCT02040506 (Clinical Trial / IGN523)
- NCT00352131 (Clinical Trial/ IMGN242 / HuC242-DM4)
- NCT00620607 (CLINICAL TRIAL / IMGN242 / HUC242-DM4)
- NCT00721669 (Clinical Trial / IMGN388)
- NCT01534715 (Clinical Trial / IMGN529)
- NCT01609556 (Clinical Trial / IMGN853 / mirvetuximab soravtansine)
- NCT01638936 (Clinical Trial / BT062 / Indatuximab ravtansine)
- NCT01001442 (Clinical Trial/ BT062 / Indatuximab ravtansine)
- NCT00723359 (Clinical Trial/ BT062 / Indatuximab ravtansine)
- NCT02391038 (Clinical Trial/ Indusatumab vedotin / MLN0264)
- NCT02202785 (Clinical Trial/ Indusatumab vedotin / MLN0264)
- NCT02202759 (Clinical Trial/ Indusatumab vedotin / MLN0264)
- NCT01577758 (Clinical Trial/ Indusatumab vedotin / MLN0264)
- NCT01055496 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT02311998 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT00868608 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT00867087 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)
- NCT01664910 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT01925131 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)
- NCT01363297 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)
- NCT01232556 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT00562965 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)
- NCT01564784 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)
- NCT01535989 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT00073749 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT01679119 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT01562990 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT01134575 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT00724971 (Clinical Trial Inotuzumab Ozogamicin / CMC-544)
- NCT00299494 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT00717925 (Clinical Trial / inotuzumab ozogamycin / CMC-544)
- NCT01371630 (Clinical Trial / Inotuzumab ozogamycin / CMC-544)
- NCT01605318 (Clinical Trial/ Labetuzumab-SN-38 / IMMU-130 / hMN-14-SN38)
- NCT01270698 (Clinical Trial/ Labetuzumab-SN-38 / IMMU-130 / hMN-14-SN38)
- NCT01915472 (Clinical Trial/ Labetuzumab-SN-38 / IMMU-130 / hMN-14-SN38)
- NCT01995188 (Clinical Trial/ Lifastuzumab vedotin / anti-NaPi2b ADC / RG-7599 / DNIB0600A)
- NCT01363947 / Study DNB4987g (Clinical Trial/ Lifastuzumab Vedotin / Anti-NaPi2b ADC / RG-7599 / DNIB0600A)
- NCT01991210 (Clinical Trial / DNIB0600A / Lifastuzumab Vedotin / Anti-NaPi2b ADC / RG-7599)
- NCT02221505 (Clinical Trial / LOP628)
- NCT02452554 (Clinical Trial / Lorvotuzumab Mertansine / BB-10901 / IMGN-901)
- NCT02420873 (Clinical Trial / Lorvotuzumab Mertansine / BB-10901 / IMGN-901)
- NCT01237678 (CLINICAL TRIAL / IMGN-901 / LORVOTUZUMAB MERTANSINE / BB-10901)
- NCT00991562 (CLINICAL TRIAL/ IMGN-901/ LORVOTUZUMAB MERTANSINE/ BB-10901)
- NCT00346255 (Clinical Trial / Lorvotuzumab Mertansine / BB-10901 / IMGN-901)
- NCT00944905 (Clinical Trial / MDX-1203)
- NCT00796055 (Clinical Trial / MEDI-547)
- NCT01101594 (Clinical Trial / hLL1-DOX / IMMU-110)
- NCT00070837 (Clinical Trial / MLN-2704)
- NCT00052000 (Clinical Trial / MLN-2704)
- NCT01891669 (Clinical Trial / PF-06263507)
- NCT01691898 (Clinical Trial / DCDT2980S / Pinatuzumab Vedotin / RG-7593)
- NCT01209130 (Clinical Trial / Pinatuzumab Vedotin / DCDT2980S / RG-7593)
- NCT01992653 (Clinical Trial / Polatuzumab Vedotin / DCDS4501A / RG-7596)
- NCT02257567 (Clinical Trial / Polatuzumab Vedotin / DCDS4501A / RG-7596)
- NCT01290549 (Clinical Trial / DCDS4501A / Polatuzumab Vedotin / RG-7596)
- NCT02020135 (Clinical Trial / PSMA ADC)
- NCT01695044 (Clinical Trial / PSMA ADC)
- NCT01414283 (Clinical Trial / PSMA ADC)
- NCT01414296 (Clinical Trial / PSMA ADC)
- NCT01432353 (Clinical Trial / DFRF4539A / RG-7598)
- NCT01856933 (Clinical Trial / PSMA ADC)
- NCT02422979 (Clinical Trial / DFRF4539A / RG-7598)
- NCT01901653 (Clinical Trial / SC16LD6.5 / rovalpituzumab tesirine (Rova-T))
- NCT01969643 (Clinical Trial / SGN-LIV1A)
- NCT01335958 (Clinical Trial / DMUC5754A / Sofituzumab Vedotin)
- NCT01283373 (Clinical Trial / Vandortuzumab Vedotin / DSTP3086S)
- NCT01774071 (Clinical Trial / Vandortuzumab Vedotin (DSTP3086S / RG7450 / MSTP2109A)
- NCT01015911 (Clinical Trial / Vorsetuzumab Mafodotin / SGN-75)
- NCT01677390 (Clinical Trial / Vorsetuzumab Mafodotin / SGN-75)
- NCT00882102 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT02139592 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01920932 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02280785 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01909934 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00365274 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02227433 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01060904 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01841021 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01950364 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01309789 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02243436 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01830777 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00354107 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01578967 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02275598 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02298283 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02191930 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01703949 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00337194 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)
- NCT01777152 (ECHELON-2) (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01596218 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01534078 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00866047 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00099255 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)
- NCT01026233 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01868451 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02292979 (BREACH Trial / EORTC-20113) (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00947856 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00848926 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01396070 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01994850 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02098512 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01476410 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01712490 / echeolon-1 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01352520 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00051597 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-30 / ADCETRIS®)
- NCT00079755 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01196208 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT01569204 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00649584 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT00430846 (CLINICAL TRIAL / BRENTUXIMAB VEDOTIN / SGN-035 / ADCETRIS®)
- NCT02398240
- NCT02408042
- NCT00284804 (Clinical Trial / MDX-060)
- NCT02429375
- NCT01869803 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00968071 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00968071 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01409161 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01548911 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00658814 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00274781 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00673153 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00766116 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00895934 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT02473146 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00038831 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00006265 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT02221310 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00669890 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00038805 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00860639 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00927498 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00085709 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00233909 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00143975 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00195000 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00372593 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01039363 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00798213 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00893399 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT02117297 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT02182596 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01698879 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00006122 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00091234 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00577694 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00089050 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00049179 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00017589 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00008151 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00070174 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00304447 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00037596 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00551460 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00476541 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01041040 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00077116 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00049517 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00052299 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00037583 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00044733 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00121303 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01407757 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00161668 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00909168 (MYFLAI07) (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00460447 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01020539 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00003131 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00003673 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00454480 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00028899 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00022321 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00962767 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT02272478 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00413166 (Clinical Trial / Gentuzumab Ozogamicin)
- NCT00005962 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01723657 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00136084 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT00492856 (Clinical Trial / Gemtuzumab Ozogamicin)
- NCT01745965 (Clinical Trial / Ado-Trastuzumab Emtansine)
- NCT01983501 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02070094 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02326974 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02236000 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00943670 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01853748 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01976169 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00875979 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01835236 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01196052 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02038010 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00679341 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00829166 (EMILIA) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00509769 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00679211 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02414646 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01419197 (TH3RESA) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01565200 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01641939 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01816035 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02289833 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02226276 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02314481 (DARWIN II) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00928330 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01597414 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00934856 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00951665 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01975142 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01120561 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01702558 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00781612 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01966471 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02073487 (TEAL) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01702571 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02131064 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01772472 (KATHERINE) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02390427 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01513083 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02135159 (BIRTH) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01042379 (I-SPY 2 Trial) (Clinical Trial)
- NCT02144012 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02073916 (STELA) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT00833963 (MotHER) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02305641 (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT02318901 (PembroMab) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- NCT01904903 (SAFE-HEaRt) (Clinical Trial/ Ado-Trastuzumab Emtansine)
- Can an ADC be Greater than the Sum of Its Parts?
- Changing Strategies in the War on Cancer – 2
- Changing Strategies in the War on Cancer – 3
- Package Inserts -Antibody-drug Conjugates
Over the last decade, and after the approval of a number of antibody-drug conjugates, the field of ADCs has gained significant momentum. With ongoing research efforts, scientists have been successful in developing a great number of antibody-drug conjugates to treat a wide array of solid and liquid tumors.
The new Expert/Knowledge Center, which includes a new ADC drug map, is designed to offer a visual overview – linked to all relevant information – of all currently approved ADCs and ADCs in clinical development.